Zyprexa Medicaid Cost Highlight Of OIG’s Mental Health Rx Spending Report
Executive Summary
The HHS Office of Inspector General's report on Medicaid spending for mental health drugs singles out Lilly's Zyprexa (olanzapine) as a particularly costly product for the program
You may also be interested in...
Lipitor Payments Under Medicaid Vary By 12% – IG
Some states paid as much as 12% more than the lowest paying states for identical units of Pfizer's Lipitor in fiscal year 2001, a report from the HHS Office of Inspector General concludes
Lipitor Payments Under Medicaid Vary By 12% – IG
Some states paid as much as 12% more than the lowest paying states for identical units of Pfizer's Lipitor in fiscal year 2001, a report from the HHS Office of Inspector General concludes
HHS IG To Study EPO, OxyContin Reimbursement In 2004 Reports
The HHS' Inspector General plans to study the "appropriateness" of epoetin alfa Medicare reimbursements for patients who have not been diagnosed with end stage renal disease